← Back to Clinical Trials
Recruiting NCT06209996

NCT06209996 A Weight Management Intervention for Overweight Chinese Cancer Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06209996
Status Recruiting
Phase
Sponsor The University of Hong Kong
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 102 participants
Start Date 2024-10-31
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
L4 weight management interventionActive control

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 102 participants in total. It began in 2024-10-31 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to conduct a feasibility trial to examine the feasibility and acceptability of conducting a randomized controlled trial that evaluates the effect of the weight management intervention on anthropometric measures (body weight and BMI), dietary quality, physical activity levels, physical and psychosocial functioning, self- efficacy for weight loss and quality of life.

Eligibility Criteria

Inclusion Criteria: * Chinese cancer survivors attending the one-off face-to-face survivorship care clinic * who are Cantonese- or Mandarin- speaking * aged 18 or above * diagnosed with early-stage disease (stage 0-II) * have completed primary and adjuvant treatments such as chemotherapy and radiotherapy * and with a BMI ≥ 23 kg/m2, as indicative as overweight or obesity using Asia-Pacific BMI cutoffs at 3-months reassessment Exclusion Criteria: * Non-Chinese survivors with advanced or metastatic disease * who have communication difficulties, mobility impairment or cognitive disabilities

Contact & Investigator

Central Contact

Danielle Ng, PhD

✉ dwlng@hku.hk

📞 +852 39179897

Principal Investigator

Danielle Ng, PhD

PRINCIPAL INVESTIGATOR

School of Public Health, The University of Hong Kong

Frequently Asked Questions

Who can join the NCT06209996 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06209996 currently recruiting?

Yes, NCT06209996 is actively recruiting participants. Contact the research team at dwlng@hku.hk for enrollment information.

Where is the NCT06209996 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT06209996 clinical trial?

NCT06209996 is sponsored by The University of Hong Kong. The principal investigator is Danielle Ng, PhD at School of Public Health, The University of Hong Kong. The trial plans to enroll 102 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology